No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Tuesday, March 24, 2026
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Business

How Is Regency Centers’ Stock Performance Compared to Other Real Estate Stocks?

by TheAdviserMagazine
1 day ago
in Business
Reading Time: 2 mins read
A A
How Is Regency Centers’ Stock Performance Compared to Other Real Estate Stocks?
Share on FacebookShare on TwitterShare on LInkedIn


With a market cap of $13.7 billion, Regency Centers Corporation (REG) is a leading national owner, operator, and developer of shopping centers in suburban areas with strong demographics. Its portfolio features high-performing properties anchored by top grocers, restaurants, service providers, and premium retailers.

Companies valued at $10 billion or more are generally considered “large-cap” stocks, and Regency Centers fits this criterion perfectly. The company focuses on creating vibrant centers that connect with local communities and customers.

Shares of the Jacksonville, Florida-based company have declined 4.7% from its 52-week high of $79.89. REG stock has risen 9.5% over the past three months, outpacing the State Street Real Estate Select Sector SPDR ETF’s (XLRE) 1.7% rise over the same time frame.

www.barchart.com

REG stock is up 9.7% on a YTD basis, outperforming XLRE’s 1.3% gain. Moreover, shares of the shopping center REIT have increased 5.9% over the past 52 weeks, compared to XLRE’s 1.5% drop over the same time frame.

The stock has been moving above its 50-day moving average since January.

www.barchart.com
www.barchart.com

Shares of Regency Centers Corporation fell marginally following its Q4 2025 results on Feb. 5 as full-year NAREIT FFO came in at $4.64 per share, missing the consensus estimate. Investors were also cautious about mixed occupancy trends, with the same property leased rate at 96.5% (down 10 bps year-over-year) and anchor occupancy declining 70 bps, indicating some softness in key large-format tenants.

In comparison, rival Simon Property Group, Inc. (SPG) has lagged behind Regency Centers stock on a YTD basis, with SPG stock rising marginally. However, SPG stock has risen 14.6% over the past 52 weeks, exceeding REG stock.

Despite the stock’s outperformance on a YTD basis, analysts remain cautiously optimistic on REG. The stock has a consensus rating of “Moderate Buy” from 21 analysts in coverage, and the mean price target of $81.21 represents a premium of 6.6% to current levels.

On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com



Source link

Tags: centerscomparedEstateperformanceRealRegencystockstocks
ShareTweetShare
Previous Post

Tax refunds are up from a year ago. Will that help the burn of higher gas prices?

Next Post

May the 4th Be With You Stock Trading Contest

Related Posts

edit post
D-Street rebounds as US halts Iran strikes; Nifty jumps nearly 2%

D-Street rebounds as US halts Iran strikes; Nifty jumps nearly 2%

by TheAdviserMagazine
March 24, 2026
0

Mumbai: Indian equities on Tuesday expectedly tracked a pan-Asian rebound in risk assets to climb nearly 2% while the rupee...

edit post
BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit (NASDAQ:BCDA)

BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit (NASDAQ:BCDA)

by TheAdviserMagazine
March 24, 2026
0

Earnings Call Insights: BioCardia (BCDA) Q4 2025 Management View Peter Altman, CEO, highlighted that BioCardia now has complete and final...

edit post
Fractyl Health outlines 2026 De Novo submission plans with pivotal Revita data expected in early Q4 (NASDAQ:GUTS)

Fractyl Health outlines 2026 De Novo submission plans with pivotal Revita data expected in early Q4 (NASDAQ:GUTS)

by TheAdviserMagazine
March 24, 2026
0

Follow us on Google for the latest stock newsFollow Seeking Alpha on Google for the latest stock newsEarnings Call Insights:...

edit post
Moldova imposes 60-day energy emergency after Russian strikes in Ukraine

Moldova imposes 60-day energy emergency after Russian strikes in Ukraine

by TheAdviserMagazine
March 24, 2026
0

Moldova’s Parliament voted on Tuesday to impose a state of emergency in the country’s energy sector after Russian strikes on neighboring...

edit post
Private sector growth hits 3.5-year low in March

Private sector growth hits 3.5-year low in March

by TheAdviserMagazine
March 24, 2026
0

New Delhi: India's private sector growth slowed to its weakest pace in more than three-and-a-half years in March as the...

edit post
Smithfield signals .325B–.475B adjusted operating profit target for 2026 while advancing major Sioux Falls investment (NASDAQ:SFD)

Smithfield signals $1.325B–$1.475B adjusted operating profit target for 2026 while advancing major Sioux Falls investment (NASDAQ:SFD)

by TheAdviserMagazine
March 24, 2026
0

Earnings Call Insights: Smithfield Foods (SFD) Q4 2025 Management View Shane Smith, President and CEO, described 2025 as "an outstanding...

Next Post
edit post
May the 4th Be With You Stock Trading Contest

May the 4th Be With You Stock Trading Contest

edit post
Are You a Job-Hugger? 5 Ways Clinging to a Bad Job Will Cost You

Are You a Job-Hugger? 5 Ways Clinging to a Bad Job Will Cost You

  • Trending
  • Comments
  • Latest
edit post
Foreclosure Starts are Up 19%—These Counties are Seeing the Highest Distress

Foreclosure Starts are Up 19%—These Counties are Seeing the Highest Distress

February 24, 2026
edit post
7 States Reporting a Surge in Norovirus Cases

7 States Reporting a Surge in Norovirus Cases

February 22, 2026
edit post
Publix to Open 5 New Stores by End of April. See Upcoming Locations.

Publix to Open 5 New Stores by End of April. See Upcoming Locations.

March 20, 2026
edit post
The Growing Movement to End Property Taxes Continues in Kentucky, And What It Means For Investors

The Growing Movement to End Property Taxes Continues in Kentucky, And What It Means For Investors

March 2, 2026
edit post
Who Is Legally Next of Kin in North Carolina?

Who Is Legally Next of Kin in North Carolina?

February 28, 2026
edit post
Georgia’s 0 Tax Rebate Is Moving Forward — Here’s When You Can Expect Your 2026 Check

Georgia’s $250 Tax Rebate Is Moving Forward — Here’s When You Can Expect Your 2026 Check

March 21, 2026
edit post
How Is Regency Centers’ Stock Performance Compared to Other Real Estate Stocks?

How Is Regency Centers’ Stock Performance Compared to Other Real Estate Stocks?

0
edit post
DoorDash Offering Relief Program to its Drivers as Gas Prices Rise

DoorDash Offering Relief Program to its Drivers as Gas Prices Rise

0
edit post
Bitcoin, XRP Rallies Won’t Hold Until Oil Falls Toward , Expert Warns

Bitcoin, XRP Rallies Won’t Hold Until Oil Falls Toward $80, Expert Warns

0
edit post
D-Street rebounds as US halts Iran strikes; Nifty jumps nearly 2%

D-Street rebounds as US halts Iran strikes; Nifty jumps nearly 2%

0
edit post
BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit (NASDAQ:BCDA)

BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit (NASDAQ:BCDA)

0
edit post
Simply Safe Dividends Review – Is It Worth the Price?

Simply Safe Dividends Review – Is It Worth the Price?

0
edit post
Bitcoin, XRP Rallies Won’t Hold Until Oil Falls Toward , Expert Warns

Bitcoin, XRP Rallies Won’t Hold Until Oil Falls Toward $80, Expert Warns

March 24, 2026
edit post
D-Street rebounds as US halts Iran strikes; Nifty jumps nearly 2%

D-Street rebounds as US halts Iran strikes; Nifty jumps nearly 2%

March 24, 2026
edit post
BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit (NASDAQ:BCDA)

BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit (NASDAQ:BCDA)

March 24, 2026
edit post
DoorDash Offering Relief Program to its Drivers as Gas Prices Rise

DoorDash Offering Relief Program to its Drivers as Gas Prices Rise

March 24, 2026
edit post
Fractyl Health outlines 2026 De Novo submission plans with pivotal Revita data expected in early Q4 (NASDAQ:GUTS)

Fractyl Health outlines 2026 De Novo submission plans with pivotal Revita data expected in early Q4 (NASDAQ:GUTS)

March 24, 2026
edit post
Shipping Firms Quietly Pay Iran Millions to Navigate Hormuz Corridor – Bitcoin News

Shipping Firms Quietly Pay Iran Millions to Navigate Hormuz Corridor – Bitcoin News

March 24, 2026
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • Bitcoin, XRP Rallies Won’t Hold Until Oil Falls Toward $80, Expert Warns
  • D-Street rebounds as US halts Iran strikes; Nifty jumps nearly 2%
  • BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit (NASDAQ:BCDA)
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.